8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 10, 2022

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-50761	11-3146460
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
14 Plaza Drive Latham, New York                         12110
(Address of Principal Executive Offices)                 (Zip Code)
(518) 795-1400
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ANGO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 – Regulation FD Disclosure.

On August 10, 2022, Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer of AngioDynamics, Inc. (“AngioDynamics”), will present at the Canaccord Genuity 42nd Annual Growth Conference. The presentation slides are furnished herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects”, “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2022. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Item 9.01 – Financial Statements and Exhibits.

(d)        Exhibits.

Exhibit No.	Description
99.1	Presentation slides for the Canaccord Genuity 42nd Annual Growth Conference, dated August 10, 2022.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANGIODYNAMICS, INC. (Registrant)
Date:  August 10, 2022	By:	/s/  Richard C. Rosenzweig
		Name:  Richard C. Rosenzweig
		Title:  Senior Vice President, General Counsel and Secretary

EX-99.1

Exhibit 99.1

 08 | 10 | 2022  ANGIODYNAMICS  Canaccord Growth Conference  Stephen Trowbridge, EVP & CFO  1 

 2  Notice Regarding Forward-Looking Statements  This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of  operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward- looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2022. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.  In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the  European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.  Notice Regarding Non-GAAP Financial Measures  Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should  consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP. 

 3  FOCUSED TRANSFORMATION  U.S. Total Addressable Markets  FY2021  Launch of the Auryon System gives us access to the peripheral atherectomy market  $3.0B  2-5% Mkt CAGR  $6.0B  3-7% Mkt CAGR  $8.0B  3-7% Mkt CAGR  FY2023  Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase market access  The planned portfolio additions and new indications are not guarantees of future performance and are subject to risks and uncertainties  including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations.  FY2025  Planned Thrombectomy & PE portfolio additions & new indications increase market access  FY2018  Began our strategic initiative to become a growth company  $1.3B  0-3%  Mkt CAGR 

 4  MED DEVICE  Maintain Positioning  Solid Tumor  Irreversible Electroporation  Peripheral Arterial Disease  MED TECH  Invest for Growth  Thrombus Management 

 THROMBUS MANAGEMENT  MED TECH 

 $80M  $2.1B  $1.8B  Deep Vein  Thrombosis  Pulmonary Embolism  PE  A blood clot that forms in a deep vein, usually the leg, groin or arm  A DVT breaks free from a  vein wall and travels to the lungs blocking some or all of the blood supply  Stages of Clot  Clot in Transit  (traveling through the heart)  Clot in Pulmonary Arteries (PE)  Plovanic, W. J., & Furlong, C. (2020, June). Inari Medical Biomedical Devices and Services. Canaccord Genuity Capital Markets.  “Venous Thromboembolism (VTE).” World Thrombosis Day, www.worldthrombosisday.org/issue/vte. Illustrations and Images not Produced by AngioDynamics Include: https://www.vascularmedcure.com/disease-background  DVT (Blood Clot In the Leg): 7 Warning Signs and Symptoms (emedicinehealth.com)  6  PULMONARY  EMBOLISM*  RIGHT ATRIUM  $3.9B  DEEP VEIN THROMBOSIS  2022 Market TAM  Source: Management estimate & industry sources.  *Includes Clot in Transit  DVT +  = VTE  DVT and PE are collectively referred to as VTE  Venous  Thromboembolism  100,000 VTE-Related Deaths in the USA Annually2 

 The  Difference  The AngioVac System allows for the continuous aspiration of embolic material such as fresh,  soft thrombi or vegetation from the venous system  Utilizing a self-expanding, nitinol reinforced funnel tip  Simultaneously reinfusing the patient’s own filtered blood  to limit procedural blood loss  Waste Collection System  Filter  Saline  AngioVac Cannula  Reinfusion Cannula  AngioVac  Circuit  7  Centrifugal Pump  Console  Individual experience may not be indicative of all procedure results. 

 Control Features for Handle & Cannula  SYRINGE BARREL  Aspirate between 10 & 30cc / pull  VOLUME LIMITING SWITCH  Allows tailored aspiration volume  VACUUM LOCK  Allows for continuous aspiration When engaged in clot  MANUAL ASPIRATION HANDLE  Controlled, single-hand design  MULTIPLE TIP ANGLES  00, 200, 850, 1800  PROPRIETARY FUNNEL DESIGN  Allows for Massive Clot Removal | En Bloc  RADIOPAQUE MARKERS  Better Tip Visibility  LARGE END HOLE ASPIRATION 42FR & 30FR  Opening  COMPLETE CONTROL INTUITIVELY SIMPLE EFFICIENTLY POWERFUL 

 9  Addressable Markets  Pulmonary Embolism (PE)  $1.6B TAM  AlphaVac F18  Isolated Inferior Vena Cava (IVC) Thrombus  $400M TAM  AlphaVac F22, F18  Iliofemoral Deep Vein Thrombosis (DVT)  $1.7B TAM  AlphaVac F14  TAMs: Management estimate & industry sources  *AlphaVac F1420 is not cleared by the Food and Drug Administration (FDA). These statements and the subject products have not been evaluated by the FDA. These devices are not currently being marketed, nor are they available for sale in any country. AlphaVac and AngioVac are not indicated for PE.  Funnel Tip Opening FR Size  Cannula Angle  Degree  Cannula FR Size  Modality Type  F2220  F22180  F1885  F1420  F1885  PE  42FR  42FR  33FR  ~21FR  33FR  20º  180º  85º  20º  85º  22FR  22FR  18FR  ~14FR  18FR  Cannula  Cannula  Cannula  Cannula  Cannula  25FR  25FR  22FR  ~16FR  22FR  Sheath  Sheath  Sheath  Sheath  Sheath  Deliberate Attention to Key Technology Elements  Shapes, Sizes and Angles will be available in both on/off circuit options (AlphaVac/AngioVac)  Availability  IN CURRENTLY DEVELOPMENT ENROLLING  Right Atrium  $80M TAM  AngioVac F22, F18  LAUNCHED LAUNCHED LAUNCHED  Clot in Transit  $170M TAM  AngioVac F22, F18 

 PERIPHERAL ATHERECTOMY  MED TECH 

 63%  37%  $760M  Over 8 Million1 Americans Suffer from P AD  Over 150,000 Limbs2 are Lost Every Year  because of PAD  50% Mortality Rate2 Associated with PAD after Limb Loss  PERIPHERAL ATHERECTOMY  US Addressable Markets & Competitive Landscape  3. Peripheral Vascular Devices Medtech 360 Market Analysis US December, 2021. Millennium Research Group, Inc.  11  2022 Served Market  https://www.nhlbi.nih.gov/health/peripheral-artery-disease  https:// www.cookmedical.com/peripheral-intervention/10-facts-about- peripheral-arterial-disease/  Above the Knee (ATK)  Below the Knee (BTK)  14%  86% Mechanical  Laser  62%  38%  Office Based Lab (OBL)  Hospital 

 2.35 mm  Aspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR)  2.0 mm  Aspiration capability and indicated for Peripheral Atherectomy and ISR  1.5 mm  Indicated for Peripheral Atherectomy  Why wavelength matters  Each type of tissue interacts differently with a given wavelength  Why pulse width and amplitude matter  Greater amplitude is  achieved with shorter  pulses, which can deposit energy before thermal diffusion occurs.  The Auryon System produces a photon energy of 3.5 eV, which is low enough to be nonreactive to vessel endothelium,  but high enough to vaporize calcium.1,2  The Auryon System has a pulse width of  10 to 25 ns, ensuring enough power to target the lesion and spare the vessel.3  0.9 mm  Indicated for Peripheral Atherectomy  Herzog A, Bogdan S, Glikson M, I s h a a y a AA, Love C. Selective t issue ablation u s in g laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287.  Spectranetics Corporation. CVX-300 Excimer Laser System: Operator’s Manual. Version 28. 2019:1-56.  Auryon. Instructions for use. AngioDynamics; 2019.   12 

 IRREVERSIBLE ELECTROPORATION  MED TECH  13 

 INNOVATION DOCTORS NEED  Expands treatment options and help preserve patient's quality of life  DECELLULARIZATION  Destroys targeted tissue with precise treatment margins.1,2  PROBE PLACEMENT  NanoKnife can be confidently used in all segments of an organ.1,2  NON-THERMAL  Spares vital structures by retaining the structural integrity of tissue.3,4  REVASCULARIZATION  Facilitates functional tissue regeneration post-ablation.3,4  Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. (2010);4(SUPPL. 1):99–104. doi: 10.5009/gnl.2010.4.S1.S99  Guidance for Selection of NanoKnife Probe Array Configuration and Ablation parameters for the Treatment of Stage III Pancreatic Cancer.  Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol. 2018 Sep;24(5):268-275. doi: 10.5152/dir.2018.17374. PMID: 30211680; PMCID: PMC6135060.  Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011 Apr 14;6(4):e18831. doi: 10.1371/journal.pone.0018831. PMID: 21533143; PMCID: PMC3077412.  14 

 $1.6B  15  21%1,2  9%1,2  PROSTATE  70%1,2  2022 Total Addressable Market (TAM)  PANCREAS LIVER  THE NANOKNIFE SYSTEM  Estimated # of US Patients Diagnosed in 20221  Liver  41,260  Pancreas  62,210  Prostate  268,490 

 Prostate cancer (PCa) is the only solid tumor without a standardized local treatment option1  Advances in genetics, imaging, and methodology support a local treatment option for PCa2  But existing technology has less than ideal outcomes for cancer control and quality of life3,4  16  Approximately  100,000  men are estimated to be candidates for focal therapy each year8  PROSTATE INITIATIVE  Effectively destroys targeted tissue with precise treatment margins5  Spares vital structures within the ablation zone6  Enables treatment to be performed in all segments of an organ7  Bridge the gap between an active surveillance strategy and whole-gland treatment  NCCN Guidelines for Patients Early Stage Prostate Cancer. https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf.  Lee, Byron H., et al. “Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy.” Imaging and Focal Therapy of Early Prostate Cancer, 2012, pp. 17–36., doi:10.1007/978-1-62703-182-0_2. 3). Worrell Design. Next Gen Voice of Customer, 2020.  Sivaraman A, Barret E. Focal Therapy for Prostate Cancer: An "À la Carte" Approach. Eur Urol. 2016;69(6):973-975. doi:10.1016/j.eururo.2015.12.015  Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. (2010);4(SUPPL. 1):99–104. doi: 10.5009/gnl.2010.4.S1.S99  Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011 Apr 14;6(4):e18831. doi: 10.1371/journal.pone.0018831. PMID: 21533143; PMCID: PMC3077412.  7). Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol. 2018 Sep;24(5):268-275. doi: 10.5152/dir.2018.17374. PMID: 30211680; PMCID: PMC6135060. 

 Prostate cancer (PCa) is the only solid tumor without a standardized local treatment option1  Advances in genetics, imaging, and methodology support a local treatment option for PCa2  But existing technology has less than ideal outcomes for cancer control and quality of life3,4  16  Approximately  100,000  men are estimated to be candidates for focal therapy each year8  PROSTATE INITIATIVE  Effectively destroys targeted tissue with precise treatment margins5  Spares vital structures within the ablation zone6  Enables treatment to be performed in all segments of an organ7  Bridge the gap between an active surveillance strategy and whole-gland treatment  NCCN Guidelines for Patients Early Stage Prostate Cancer. https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf.  Lee, Byron H., et al. “Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy.” Imaging and Focal Therapy of Early Prostate Cancer, 2012, pp. 17–36., doi:10.1007/978-1-62703-182-0_2. 3). Worrell Design. Next Gen Voice of Customer, 2020.  Sivaraman A, Barret E. Focal Therapy for Prostate Cancer: An "À la Carte" Approach. Eur Urol. 2016;69(6):973-975. doi:10.1016/j.eururo.2015.12.015  Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. (2010);4(SUPPL. 1):99–104. doi: 10.5009/gnl.2010.4.S1.S99  Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011 Apr 14;6(4):e18831. doi: 10.1371/journal.pone.0018831. PMID: 21533143; PMCID: PMC3077412.  7). Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol. 2018 Sep;24(5):268-275. doi: 10.5152/dir.2018.17374. PMID: 30211680; PMCID: PMC6135060. 

 17  PRESERVE Prostate IDE  37  SUO-CTC US sites responded to Call for Sites  20  Sites selected, focused on geographic and demographic diversity, high-volume focal therapy institutions  118  Intermediate-risk patients to be enrolled through 1-year follow up  SUO-CTC is a clinical research investigator network of 500+ members from more than 250 clinical sites in the US and Canada.  Primary Endpoint: Rate of negative in-field biopsy at 1 year  First Patient Enrolled: April 2022  Enrollment Period: 12 months  Date of last update: April 7, 2022 

 18  TECHNOLOGY PLATFORM PIPELINE 

 Med Tech Platform Expansions  Developing our Med Tech platforms exponentially expands our TAMs  FY2023 TAM  $6B  Portfolio Expansion  Pulmonary Embolism  Left Atrium  Coronary  Atherectomy*  Arterial Thrombectomy  European MedTech Platform Expansion*  DVT  Atherectomy  Right Atrium  Prostate  Med Device  Chronic DVT*  Future TAM  >$10B  Source: Management estimate & industry sources  Note: The planned portfolio additions are not guarantees of future performance and are subject to risks and uncertainties, including clearance by the FDA. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations.  *Facilitates incremental TAM expansion beyond that depicted for FY 2025 on the previous slide  19 

 20  Peripheral Arterial Disease (PAD) Atherectomy  Arterial Thrombectomy  Venous Thrombectomy  Coronary  Expansion Opportunity  ~$1B TAM  Medial Calcification Treatment  Claims Expansion  Opportunity  Coronary Artery Disease (CAD) Atherectomy  PAD Interoperative Thrombus  NEW Indication Received $50M TAM  Acute Limb Ischemia (ALI)  Indication Expansion Opportunity  $850M TAM  In Stent Restenosis (BTK) Above the Knee (ATK) Below the Knee (BTK)  Current Indications  $760M Served  Medial Calcification Treatment  Claims Expansion Opportunity  ~$1B TAM  Iliofemoral DVT Chronic Clot  In Development  $1.7B TAM  Procedural Hub at all Sites of Service OBL/ASC/Hospital  Technology and Platform  Expansion Pipeline  Funded Development Project  Commercially Available  TAMs: Management estimate & industry sources 

 21  Right Atrium  Venous Thrombectomy  Pulmonary Embolism  Left Atrium  Infective Endocarditis (IE)  Current Indications  $80M TAM  Clot in Transit  $170M TAM  Isolated IVC  Current Indications $400M TAM  Iliofemoral DVT  Current Indication, Optimized 14F w/ retractor in development  $1.7B TAM  Pulmonary Embolism  IDE Currently Enrolling  $1.6B TAM  Infective Endocarditis (IE) Left Atrial Appendage Thrombus (LAA)  In Development  $430M TAM  Funded Development Project  Commercially Available  Technology and Platform Expansion Pipeline  TAMs: Management estimate & industry sources 

 22  Prostate  Pancreas  Liver  Salvage  FIRE Trial*  $119M TAM  Intermediate  PRESERVE Trial  $585M TAM  Stage IIB & III  Breakthrough Designation & DIRECT Study  $60M TAM  Tumor Ablation  META Data Analysis  $114M TAM  Funded Development Project  Commercially Available  Technology and Platform Expansion Pipeline  TAMs: Management estimate & industry sources  * Focal Irreversible Electroporation as salvage treatment in radio-recurrent prostate cancer, Investigator initiated trial 

 FINANCIALS  23 

 Fourth Quarter and Full-Year Highlights  Q4 FY2022  Q4 FY2021  Change  FY2022  FY2021  Change  Revenue  $86,998  $76,842  13.2%  $316,219  $291,010  8.7%  Gross Margin  53.4%  55.1%  (170 bps)  52.4%  53.9%  (150 bps)  Net Loss  ($6,266)  ($19,468)  $13,202  ($26,547)  ($31,548)  $5,001  GAAP EPS  ($0.16)  ($0.51)  $0.35  ($0.68)  ($0.82)  $0.14  Adjusted EPS  $0.01  $0.00  $0.01  $0.00  $0.05  ($0.05)  Adjusted EBITDA  $6,192  $4,512  $1,680  $20,879  $19,516  1,363  Financial Performance  $ in thousands (except per share data)  24 

 FY21 FY22  235.3  237.5  55.7  78.7  Fourth Quarter and Full-Year Highlights  25  Med Device  Med Tech  40.0% growth  6.1% growth  Q4 Revenue Growth  Q4 FY21  Q4 FY22  Full-Year Revenue Contribution  Med Device  Med Tech  FY21  FY22  41.2% growth  0.9% growth  Q4 Revenue Contribution  Full-Year Revenue Growth  21%  79%  26%  74%  60.7  64.4  16.2  22.6  Q4 FY22  Q4 FY21  19%  81%  25%  75% 

 Fourth Quarter and Full-Year 2022 Results (unaudited)  $ in thousands (except per share data)  Q4 FY2022  Q4 FY2021  Change  FY2022  FY2021  Change  Revenue  $86,998  $76,842  13.2%  $316,219  $291,010  8.7%  Med Tech  Med Device  $22,611  $64,387  $16,150  $60,692  40.0%  6.1%  $78,717  $237,502  $55,731  $235,279  41.2%  0.9%  Endovascular Therapies Vascular Access Oncology  $45,126  $26,734  $15,138  $38,071  $24,462  $14,309  18.5%  9.3%  5.8%  $160,925  $100,193  $55,101  $135,079  $101,310  $54,621  19.1%  (1.1%)  0.9%  United States International  $73,704  $13,294  $63,597  $13,245  15.9%  0.4%  $265,963  $50,256  $237,043  $53,967  12.2%  (6.9%)  Net Loss  Non-GAAP Adjusted Net Income (Loss)  ($6,266)  $253  ($19,468)  ($67)  $13,202  $320  ($26,547)  ($182)  ($31,548)  $1,852  $5,001  ($2,034)  GAAP EPS  Non-GAAP Adjusted EPS  ($0.16)  $0.01  ($0.51)  $0.00  $0.35  $0.01  ($0.68)  $0.00  ($0.82)  $0.05  $0.14  ($0.05)  Gross Margin  53.4%  55.1%  (170 bps)  52.4%  53.9%  (150 bps)  Adjusted EBITDA  $6,192  $4,512  $1,680  $20,879  $19,516  $1,363  $ in thousands  Q4 FY2022  Q4 FY2021  Change  Cash  $28,825  $48,161  ($19,336)  Debt  $25,000  $20,000  $5,000  Net (Debt) Cash  $3,825  $28,161  ($24,336)  26 

 27  Fourth Quarter and Full-Year 2022 Gross Margin Walk  Full-Year  Fourth Quarter  * Start-up costs include installation costs related to the Auryon lasers and costs related to transitioning  the manufacturing of AlphaVac to AngioDynamics. 

 28  Full-Year 2022 Cash Walk 

 APPENDIX  29 

 GAAP to Non-GAAP Reconciliation  30 

 Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS  Reconciliation of Net Loss to Adjusted EBITDA  (1)  (2)  (3)  Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write- offs, certain litigation, and other items. Fiscal year 2021 results include a $14.0 million write-off of OARtrac intangible assets.  Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended May 31, 2022 and May 31, 2021.  Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.  31  (1)  Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Fiscal year 2021 results include a $14.0 million write-off of OARtrac intangible assets.  (in thousands, except per share data)  (in thousands) 

XML

Document and Entity Information	Aug. 10, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 10, 2022
Entity File Number	000-50761
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	0001275187
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3146460
Entity Address, Address Line One	14 Plaza Drive
Entity Address, City or Town	Latham
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	12110
City Area Code	518
Local Phone Number	795-1400
Entity Emerging Growth Company	false
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ANGO
Security Exchange Name	NASDAQ